Sanofi has made no secret of its desire to be at the forefront of the digital transformation of business, and the big pharma says it will now apply leading-edge real-world evidence (RWE) analytics being developed by the high-profile US start-up Aetion to its clinical trial process.
Real-World Evidence: Sanofi Push Driven By Aetion Deal
Facilitating Regulatory-Grade Clinical Studies
Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical development process.
More from Deals
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.